|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-12-25
|
|
pubmed:abstractText |
Patients on two nucleoside analogs plus nevirapine (NVP) who show low-level plasma HIV RNA might have insufficient NVP plasma levels and therefore might benefit from an increase in NVP dosing.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-4336
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
463-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12501129-Adult,
pubmed-meshheading:12501129-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:12501129-CD4 Lymphocyte Count,
pubmed-meshheading:12501129-Drug Administration Schedule,
pubmed-meshheading:12501129-Drug Resistance, Viral,
pubmed-meshheading:12501129-Female,
pubmed-meshheading:12501129-HIV Infections,
pubmed-meshheading:12501129-HIV-1,
pubmed-meshheading:12501129-Humans,
pubmed-meshheading:12501129-Male,
pubmed-meshheading:12501129-Middle Aged,
pubmed-meshheading:12501129-Nevirapine,
pubmed-meshheading:12501129-RNA, Messenger,
pubmed-meshheading:12501129-Treatment Outcome,
pubmed-meshheading:12501129-Viral Load
|
|
pubmed:articleTitle |
Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?
|
|
pubmed:affiliation |
Service of Pharmacy, Instituto de Salud Carlos III, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
